Recipharm has inked a deal with a pharma company to support vaccine manufacturing from its facility in Kaysersberg, France. The containers will be efficiently filled using Recipharm's specialist blow-fill-seal (BFS) capabilities, creating products that are quick to distribute and simplifying administration for healthcare providers. Recipharm is investing almost EUR 14 million into its vaccine manufacturing offering at the site.

This facility has been inspected and approved by multiple regulatory agencies across the globe including ANSM (EU-GMP), FDA and Brazil's ANVISA. It also holds a number of approvals for its environmental management systems and occupational health and safety management system.